CODEINE CONTIN 150MG CONTROLLED RELEASE TAB 150 MG
CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) : 150 MG · DIN 02163780 · PURDUE PHARMA
Health Canada status: MARKETED
What is CODEINE CONTIN 150MG CONTROLLED RELEASE TAB?
CODEINE CONTIN 150MG CONTROLLED RELEASE TAB 150 MG contains CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02163780, held by PURDUE PHARMA, supplied as TABLET (EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1995. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CODEINE CONTIN 150MG CONTROLLED RELEASE TAB used for?
CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to moderate pain in adults requiring the prolonged use of an opioid analgesic preparation. CODEINE CONTIN is not indicated as an as-needed (prn) analgesic.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02163780 |
|---|---|
| Brand name | CODEINE CONTIN 150MG CONTROLLED RELEASE TAB |
| Generic / active ingredient | CODEINE (CODEINE MONOHYDRATE, CODEINE SULFATE TRIHYDRATE) : 150 MG |
| Manufacturer | PURDUE PHARMA |
| Strength | 150 MG |
| Dosage form | TABLET (EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | R05DA04 CODEINE |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1995 |
| Original market date | 1995-12-31 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
Is CODEINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by PURDUE PHARMA, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for CODEINE CONTIN 150MG CONTROLLED RELEASE TAB
What can be used instead?
Other Canadian products sharing ATC code R05DA04 CODEINE. 9 of 24 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CODEINE 30 | 30 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | DIN 02009757 |
| CODEINE CONTIN 100MG CONTROLLED RELEASE TAB | 100 MG | TABLET (EXTENDED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02163748 |
| CODEINE CONTIN 200MG CONTROLLED RELEASE TAB | 200 MG | TABLET (EXTENDED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02163799 |
| CODEINE CONTIN 50MG CONTROLLED RELEASE TAB | 50 MG | TABLET (EXTENDED-RELEASE) | PURDUE PHARMA | MARKETED | DIN 02230302 |
| CODEINE PHOSPHATE SYRUP | 25 MG / 5 ML | SYRUP | LABORATOIRE ATLAS INC | MARKETED | DIN 00050024 |
| LINCTUS CODEINE BLANC | 10 MG / 5 ML | SOLUTION | LABORATOIRE ATLAS INC | MARKETED | DIN 00380571 |
| TEVA-CODEINE | 15 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00593435 |
| TEVA-CODEINE | 30 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00593451 |
| CODEINE 15 | 15 MG | TABLET | LABORATOIRE RIVA INC. | DORMANT | DIN 02009889 |
| CODEINE PHOSPHATE INJ 30MG/ML | 30 MG / 1 ML | SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | DIN 00497282 |
Who else supplies CODEINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CODEINE appears in 25 registered pack listings across 4 markets, published on 4 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for CODEINE CONTIN 150MG CONTROLLED RELEASE TAB
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.